



IFW

S&H Form: (2/01)
DOCKET NO. 1454.1685

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Bernd SCHUERMANN et al.

Serial No: 10/571,669

Group Art Unit: 1636

Confirmation No. 3484

Filed: March 13, 2006

Examiner: Unassigned

For: IDENTIFICATION OF PHARMACEUTICAL TARGETS

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

It is requested that the Assignment for Published Patent Application on the Official Filing Receipt be corrected to specify **SIEMENS AKTIENGESELLSCHAFT of Munich, Germany**, as is evidenced by the Assignment, attached to the application as filed. For the convenience of the Patent and Trademark Office, attached is a photocopy of the original receipt on which the errors have been noted in red.

It is requested that a corrected Official Filing Receipt be issued in this application.

Respectfully submitted,

STAAS & HALSEY LLP

Date: Nov 21 2006

By: Mark J. Henry
Mark J. Henry
Registration No. 36,162

1201 New York Ave, N.W., 7th Floor
Washington, D.C. 20005
Telephone: (202) 434-1500
Facsimile: (202) 434-1501



UNITED STATES PATENT AND TRADEMARK OFFICE




UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/571,669	03/13/2006	1636	900	1454.1685	4	9	2

CONFIRMATION NO. 3484

21171
STAAS & HALSEY LLP
SUITE 700
1201 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005



FILING RECEIPT



OC000000021079482

Date Mailed: 11/06/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Bernd Schuermann, Haimhausen, GERMANY;
Martin Stetter, Munich, GERMANY;

-- Assignment for Published Patent Application: SIEMENS

Power of Attorney: The patent practitioners associated with Customer Number 21171. AKTIENGESELLSCHAFT

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/51835 08/18/2004

Munich, Germany--

Foreign Applications

GERMANY 103 42 274.9 09/12/2003

If Required, Foreign Filing License Granted: 11/02/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/571,669**

Projected Publication Date: 02/08/2007

Non-Publication Request: No

Early Publication Request: No

Title

Identification of pharmaceutical targets

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof

unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

ASSIGNMENT

For good and valuable consideration, I/we, the undersigned

Prof. Bernd Schürmann
residing at:
Münchener Str. 35
85778 Haimhausen
GERMANY

Dr. Martin Stetter
residing at:
Krauthaimstraße 33
80997 München
GERMANY

residing at:

residing at:

residing at:

residing at:

residing at:

residing at:

hereby sell, assign, and transfer to

~~Siemens Aktiengesellschaft~~

a German corporation organized and existing under the laws of the Federal Republic of Germany, having its principal place of business in München, GERMANY herein the "Assignee", its successors, assigns and legal representatives the entire and exclusive right, title and interest in and for the United States, in all and to any improvements in the

(Title:) **IDENTIFICATION OF PHARMACEUTICAL TARGETS**

disclosed in the PCT international application for Letters Patent designating the United States, said application being identified in our records as

Applicants File No. 2001P16379WOUS
and filed as PCT-application PCT/EP2004/051835

and in and to said application and all divisional, continuing substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States on any of said improvements; and in and to all original and reissued patents which have been or shall be issued in the United States on said improvements;

hereby agree that said Assignee may apply for and receive Letters Patent for said improvements in its own name and that when requested without charge to but at the expense of said Assignee, its successors, assigns, and legal representatives, to carry out in good faith the intent and purpose of this agreement, the undersigned will execute all divisional, continuing substitute, renewal, reissue and all other patent applications on any and all said improvements; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and legal representatives all facts known to the undersigned relating to said improvements and the history thereof; and generally do everything possible which said Assignee, its successors, assigns, or legal representatives shall consider desirable for aiding in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements and all applications for patents and all patents on said improvements in said Assignee, its successors, assigns, and legal representatives; and hereby covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed had been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.


Date: 09.02.06


Prof. Bernd Schürmann

Witnesses: Güger
(type name) CHRISTA SINGER

Witnesses: Jahn Dr
(type name) NATHANUS DEJORI

Date: 09.02.06


Dr. Martin Stetter

Witnesses: Güger
(type name) CHRISTA SINGER

Witnesses: Jahn Dr
(type name) NATHANUS DEJORI

Date: _____

Witnesses: _____
(type name)

Witnesses: _____
(type name)